Minutes Board Meeting MultiPark
2013-01-22, 12.00-14.00

Present:  Pia Berntsson
           Hjálmar Bjartmarz
           Anders Björklund
           Gunnar Gouras
           Susanne Iwarsson (chair)
           Elisabet Londos
           Cecilia Lundberg
           Karl Obrant
           Per Odin
           Roger Olsson
           Emma Roybon
           Martina Svensson
           Jens Schouenborg

§1. Opening of the Meeting
Susanne Iwarsson welcomed everybody and opened the meeting.

§2. Election of “Justeringsperson”
Gunnar Gouras was assigned as “Justeringsperson”.

§3. Approval of the agenda
The content of the agenda was approved.

§4. Minutes from the latest board meeting
There were no comments on the minutes from the latest board meeting. A question was
raised regarding writing the minutes in Swedish but it was decided that this question would
be raised with the new board and that the minutes at this final meeting of this board will be
in English.

§5. Delegated decisions (enclosure 1)
The Travel Grants and Other Strategic Grants that have been approved by the
coordinator/assistant coordinator are summarized in the two tables in enclosure 1. Also all
the innovation grants awarded during the last two years are listed under delegated
decisions since these decisions have not been documented in any previous board meeting
protocol.

§6. Information
• Susanne informs the Board that there is an ongoing process to appoint a new
  board for MultiPark, to be decided by the Faculty Board, 2013-02-14. Five
  external persons have accepted to be nominated as members. The Vice-
  chancellor has appointed Susanne Iwarsson as the Chair of the Board, with
  Gunnar Gouras as the Vice Chair for the period 2013-03-01 – 2014-12-31.
• Regarding the Annual Report of MultiPark, Emma Roybon mentions that the challenges in the process of compiling the report are to retrieve information from everyone in order to write a balanced report, reflecting activities across the broad spectrum of MultiPark.

• Susanne Iwarsson reports on the results from the call from the Vice Chancellor for funding of activities across the Strategic Research Area at the university. MultiPark is represented in in 4 out of the 9 successful applications, including funding for:
  o Depreciation costs for the small molecule screening infrastructure; joint application with EXODIAB, BioCare and StemTherapy
  o Organizing a course in Illustrations techniques; joint application with Stem Cell Center
  o Communication – for increased visibility of MultiPark, EXODIAB and StemTherapy
  o Bioinformatics; joint application with EXODIAB, BioCARE and EpiHealth

• Susanne Iwarsson informs about an upcoming strategic workshop in Åkersberg, engaging a purposefully selected group of MultiPark investigators, including the 10 original Pls. The purpose of the meeting is to concentrate and continue the discussions from the retreat in 2012.

• Susanne Iwarsson congratulates Per Odin who has been recommended by the Appointment Committee at the Faculty of Medicine for the position as professor in clinical neuroscience.

• Susanne Iwarsson and Emma Roybon report on some changes in the administration of MultiPark. As of February 1st, the administrative staff serving MultiPark will be as follows:
  o Emma Roybon: 100 %
  o Pia Berntsson: 25 %
  o Ulrika Mundt Petersen: 25 %

§7. Decision on continued funding of technical staff based on evaluation and recommendation by the Infrastructure Steering Group

A steering group has been formed to survey the infrastructure investments that will be made, and Jia-Yi Li is the chair of this group. One specific task of the group is to evaluate the work of Anna Hammarberg and Martin Lundblad, and based on the evaluation to make a recommendation to the Board regarding continued funding. For Martin Lundblad, who already holds a permanent position at EMV, a decision would only refer to continued funding, whereas for Anna Hammarberg, continued funding implies that she will have to re-apply for her position, and if successful, she will have a permanent position within the EMV. The informal feedback the group received was very positive, and based on the SWOT analyses made by Anna Hammarberg and Martin Lundblad, the steering group recommends that both will receive continued funding.

It is decided to set aside continued funding for Martin Lundblad until 2014-12-31 and it is decided to set aside funding for a full time position for Anna Hammarberg until 2014-12-31.
The Board would like to see the SWOT analyses referred to (attached).

§8 Update from the Working Group on Innovation

a) Report by Tadeusz Wieloch
Tadeusz Wieloch gives an account of the work of the innovation group, which is formed by Thomas Laurell, Tadeusz Wieloch and Roger Olsson. In 2011, three applications (from Per Pettersson, Karsten Ruscher, Tomas Deierborg) were funded. Two more applications were granted in 2012 (from Laurent Roybon, Agnete Kirkeby) and they are due to submit a report by the end of the year.

b) Decision on innovation officer funding, 25 %
Tadeusz Wieloch has through LUIS been able to receive 25% funding for an innovation officer for MultiPark under the condition that MultiPark finances 25%. Tadeusz Wieloch therefore suggests that part of the funds set aside for innovation grants should be allocated to fund a 25% position for an innovation officer. Cecilia Lundberg asks if there still will be sufficient funds for awarding innovation grants and Tadeusz Wieloch makes the assessment that there is room for both. The Board decides to set aside 25% of the allocated funds for innovation grants for the employment of an innovation officer provided that LUIS provides 25%.

§9. Update on declined funding for clinical research and discussion on how to reallocate funds
Susanne Iwarsson informs the Board that Ruben Smith, a clinician who has been awarded 50% funding for research time during 18 months, has been granted ALF funding. Since he was not able to combine these two types of funding, he had to decline the funding from MultiPark.

Per Odin mentions that the clinical node will use less funds than was originally planned due to, for example, the declined funding from Ruben Smith, and the fact the professorship has been delayed. He points out the need within the clinical node to continue to pay for research nurses, when current funding from SPA expiries, and suggests that the nurses should be looked upon as a research platform/infrastructure for clinical research.

Susanne Iwarsson concludes that such issues will be discussed further at the upcoming strategic workshop, and that any major deviations from the budget for 2013 must be ratified by the new Board.

§10. Update from the working group on the Strategic Plan for the Experimental Node (Gunnar Gouras)
Gunnar Gouras concludes that there are no new updates since his latest report.

§13. Other issues
Cecilia Lundberg mentions that as a board member of the Swedish Neuroscience Association she receives requests for urgent actions to lobby the Finance Ministry regarding the cut in the proportion of funds for Health in the new EU framework package,
Horizon 2020, and she asks the Board if there is anything MultiPark can do. Susanne Iwarsson believes it is too late in the process, but suggests that Cecilia Lundberg writes a note and sends to Emma, who will distribute it across MultiPark to encourage action.

§ 14. End of meeting
Susanne Iwarsson thanks the board members that will be leaving the board for their work.

[Signatures]

Susanne Iwarsson
Chairman

Emma Roybon

Justeras

Gunnar Gouras
## Travel Grants

<table>
<thead>
<tr>
<th>Name</th>
<th>Amount (SEK)</th>
<th>Conference, location &amp; date</th>
<th>Approved by</th>
<th>Supervisor / Group</th>
<th>Date of decision</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nolwen Rey</td>
<td>7 000</td>
<td>The 11th International Conference on Alzheimer’s and Parkinson’s Diseases, Florence, Italy, 6-10 March 2013</td>
<td>G Gouras</td>
<td>P Brundin</td>
<td>2012-12-17</td>
</tr>
<tr>
<td>Katarina Willén</td>
<td>7 000</td>
<td>The 11th International Conference on Alzheimer’s and Parkinson’s Diseases, Florence, Italy, 6-10 March 2013</td>
<td>S Iwarsson</td>
<td>G Gouras</td>
<td>2012-12-14</td>
</tr>
<tr>
<td>Risto Cukalevski</td>
<td>15 000</td>
<td>The 24th International Society for Neurochemistry (ISN) and American Society for Neurochemistry (ASN), Cancun, Mexico, 20-24 April 2013</td>
<td>G Gouras</td>
<td>S Linse</td>
<td>2013-01-15</td>
</tr>
</tbody>
</table>

## Other Strategic Grants

<table>
<thead>
<tr>
<th>Name</th>
<th>Amount (SEK)</th>
<th>Kind of activity</th>
<th>Approved by</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per Pettersson</td>
<td>200 000</td>
<td>Innovation grant</td>
<td>Tadeusz Wieloch</td>
<td>2011-09-09</td>
</tr>
<tr>
<td>Tomas Deierborg</td>
<td>200 000</td>
<td>Innovation grant</td>
<td>Tadeusz Wieloch</td>
<td>2011-09-09</td>
</tr>
<tr>
<td>Karsten Ruscher</td>
<td>200 000</td>
<td>Innovation grant</td>
<td>Tadeusz Wieloch</td>
<td>2011-09-09</td>
</tr>
<tr>
<td>Laurent Roybon</td>
<td>200 000</td>
<td>Innovation grant</td>
<td>Tadeusz Wieloch</td>
<td>2012-03-20</td>
</tr>
<tr>
<td>Agnete Kirkeby</td>
<td>200 000</td>
<td>Innovation grant</td>
<td>Tadeusz Wieloch</td>
<td>2012-10-01</td>
</tr>
</tbody>
</table>